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CURRENT PHARMACOTHERAPIES FOR DEPRESSION:  
COMPARING SEROTONERGIC, GLUTAMATERGIC,  
AND GABA MODULATING AGENTS 
ALEXANDER TAKACS 
ABSTRACT 
Depression is the leading cause of disability in the world.  The most common 
depression related diagnosis is major depressive disorder (MDD).  Around 7% of the 
adult population in the United States have suffered at least one major depressive episode.  
MDD demonstrates a high economic burden and comorbidity as well.  Depression is an 
incredibly complex disease in terms of cause, and patients can vary greatly in 
presentation as well as treatment outcomes.  There are many proposed pathological 
mechanisms for the development of depression, but a common cause has not been found.  
Antidepressant medications, as well as psychotherapy, have been the main stay of 
depression treatment since the 1950s.  These medications act by boosting serotonergic 
and/or adrenergic transmission. Selective serotonin reuptake inhibitors (SSRIs) are the 
most popular first-line antidepressant medications. However, only around 50% of MDD 
patients experience a response from first-line antidepressants.  The purpose of this review 
is to compare an SSRI, escitalopram, to two recently approved depression medications 
which exhibit novel mechanisms of action.  Esketamine acts on the glutamatergic system, 
while brexanolone acts on the GABAergic system.  The pharmacological properties of 
these 3 drugs were compared, through analysis of clinical trials and reviews, in order to 
determine which mechanism warrants the greater focus in future antidepressant research.  
 
 v 
Both esketamine and brexanolone showed efficacy and safety in treating their respective 
depression subtype populations.  The major difference between esketamine and 
brexanolone in comparison with escitalopram was a rapid antidepressant effect.  The 
conclusion of this review indicates that future research should perhaps focus more on 
alternative mechanisms of action than serotonergic, like glutamatergic and GABAergic 
drugs.  Future research should include studying the efficacy and safety of glutamatergic 
and GABAergic antidepressants in the MDD population.  
 
 vi 
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Depression and Major Depressive Disorder 
The most common diagnosis of depression is major depressive disorder (MDD), 
while less common diagnoses related to depression include; seasonal affective disorder, 
episodic depression, dysthymic disorder, bipolar disorder, or a psychotic disorder.43  The 
major feature of MDD is the presence of an episode of at least 2 weeks, in which an 
individual experiences either depressed mood or the loss of interest in almost all 
activities.14  The risk factors for depression are; female gender, history of an anxiety 
disorder, history of or current drug or alcohol abuse, history of an eating disorder, first-
degree relative that suffers or suffered from depression, and history of or current sexual 
abuse or domestic violence.43  Depression is the leading cause of disability in the world 
and its prevalence is increasing.  In 2017, there was an estimated 17.3 million adults in 
the United States that have experienced at least one major depressive episode, which 
equates to 7.1% of all U.S. adults.  Additionally, the prevalence of adults with a major 
depressive episode was highest among the 18-25 age range at 13.1%.38   MDD exhibits 
significant economic burden as well.  It was found that from 2005 to 2010 the economic 
burden of MDD in the United Stated increased from $173.2 billion to $210.5 billion; 
which equates to a 21.5% increase.23   This economic burden value was determined by 
the summation of estimated direct medical costs, suicide-related costs, and workplace 
costs.  Reduced productivity at work accounted for approximately 37% of the total 
economic burden of MDD in this estimation.23   The current treatment options for 




electroconvulsive therapy (ECT).  The most popular antidepressants prescribed by 
clinicians are selective serotonin-reuptake inhibitors (SSRIs) which exhibit a serotonergic 
mechanism of action.  However, only around 50% of patients with depression experience 
a response to first-line antidepressant treatment.66   Furthermore, around 33% of patients 
with MDD fail to achieve remission after treatment with multiple antidepressants.50   In 
the past year, the FDA has approved the use of two new classes of drugs for the treatment 
of depression.  One acts on the glutamatergic system, while the other acts on the 
GABAergic system. 
The severity of a MDD patient’s depression is based on the number of depressive 
symptoms present and the severity of those symptoms.  According to the ICD-10, 
International Classification of Diseases Tenth Revision, the core symptoms of depression 
are depressed mood, loss of interest in activities, and decreased energy and decreased 
activity.  The other symptoms that may be present in depression are bleak views of the 
future, reduced attention, reduced concentration, reduced self-esteem and self-confidence, 
feelings of guilt, feelings of unworthiness, thoughts or acts of self-harm or suicide, 
disturbed sleep, and reduction in appetite.12   In addition, a combination of these 
symptoms must be present for at least 2 weeks in order to constitute a major depressive 
episode.  The presence of 3 or less of these symptoms does not reach the level of MDD.  
The presence of 4 symptoms does reach the level of MDD, and corresponds to mild 
depression. In mild depression, the patient’s symptoms are not intense and cause only a 
mild impairment to work and social activities.12   The presence of 5 to 6 symptoms marks 




mild depression, and the patient experiences a moderate impairment to daily activities.  
The presence of 7 to 10 symptoms corresponds to severe depression.  In this severity of 
depression, the patient’s symptoms are severe and daily activities are heavily impaired.12   
The last category a patient with MDD can fall into is severe depression with psychotic 
symptoms.   
Treatment for Depression 
The guidelines for depression therapy are largely agreed upon among western 
countries.  The treatment of depression involves implementing a form of 
pharmacotherapy and/or psychotherapy in order to achieve remission.12   The 
determination of which form of pharmacotherapy and/or psychotherapy that is 
recommended is dependent on the severity of the patient’s depression.12   The specific 
antidepressant used for first-line treatment are second-generation antidepressants.  The 
second-generation antidepressants are SSRIs and Serotonin-Norepinephrine Reuptake 
Inhibitors (SNRI).47  There is not a specific psychotherapy that is recommended but 
commonly implemented therapies include; behavioral therapy, cognitive behavioral 
therapy (CBT), interpersonal psychotherapy (IPT), psychodynamic therapies, and 
supportive therapy.21  A combination treatment is recommended if the patient has a 
history of partial response to a single type of treatment.12  For mild depression, 
psychotherapy and pharmacotherapy have exhibited equivalent antidepressant efficacy.  
For moderate depression, antidepressant monotherapy is recommended.  Psychotherapy 
may also be considered depending on the needs of the patient.  Pharmacotherapy and 




moderate MDD and psychosocial problems or an AXIS II disorder.12  AXIS II disorders 
are personality disorders, one of which being borderline personality disorder.14  The 
specific antidepressant medications that are recommended at this severity are; second 
generation antidepressants, bupropion, or mirtazapine.12  The first-generation 
antidepressants and nefazodone are not recommended for moderate MDD because of 
decreased safety profile.12  The first-generation antidepressants are tricyclic 
antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs).47  The treatment 
options for severe depression include; concurrent pharmacotherapy and psychotherapy, 
ECT, or the combination of an antidepressant with an antipsychotic medication.  The 
latter is only recommended if the patient presents with severe MDD with psychotic 
symptoms.12   According to the World Federation of Societies of Biological Psychiatry 
(WFSBP), the most useful antidepressants for the treatment of severe depression are 
TCAs and SNRIs.  It has also been observed that psychotherapy alone exhibits less 
efficacy than antidepressant treatment at this stage.12   The anxiolytic medications, 
benzodiazepines, are also recommended for certain cases of depression.  Benzodiazepines 
can be used for catatonic and suicidal depression, but are only recommended for acute 
treatment due to abuse potential.12   





Moderate Second-generation antidepressants, bupropion, or mitrazapine 
Severe 
Psychotherapy and TCAs or SNRIs 
or 
ECT 




Table 1. Recommended Treatments for Depression Severity.  The table above depicts which treatment 
is recommended for depression patients.  It should be noted that different treatments can be recommended 
depending on patient preference or past treatment response.  Examples of these specific instances are 
described in the above paragraph.  Psychotherapy or second-generation antidepressants are recommended 
for patients suffering from mild depression.  For moderate depression, antidepressant monotherapy is 
recommended.  The antidepressants recommended at this severity are second-generation antidepressants, 
bupropion, or mirtazapine.  The recommended treatment for severe depression is either concurrent 
psychotherapy with a TCA or SNRI or ECT.  For a patient suffering from severe depression with psychotic 
symptoms, treatment with a TCA or SNRI paired with an antipsychotic medication is recommended.12 
 
The goal of the depression treatment is to achieve symptom remission.45   The 
progression of treatment is monitored by using quantitative scales to rate the presence 
and severity of the patient’s symptoms.  A commonly used scale in clinical practice is the 
Quick Inventory of Depressive Symptomatology (QIDS-16).12   This scale gives the 
patient a numerical value, based on the severity and presence of the symptoms of MDD, 
in order to track the responsiveness of a treatment.  Some guidelines disagree on what 
magnitude of response equates to remission.  The Treatment Algorithms for Depression 
(TMAP) considers remission to be improvement of symptoms to below the threshold 
criteria for MDD.  On the other hand, the WFSBP considers remission to be an 
asymptomatic state.12   However, all guidelines agree that second-line treatment options, 
after implementing an increase in dosage, are: switching, combining, or augmenting the 
initial treatment.12   If the first antidepressant results in a nonresponse, then switching to 
another antidepressant is recommended.  If the first antidepressant treatment results in a 






Figure 1. Quick Inventory of Depressive Symptomatology (QIDS-16).  Taken from (Davidson, 2018).  
This depression scale gives the patient a numerical value based on the presence, and if present, the severity 
of MDD symptoms.  A score of 0 to 5 corresponds to remission.  A score of 6 to 8 corresponds to a partial 
response to treatment.  A score of 9 or greater corresponds to a nonresponse to treatment.  A maximum 
score on the QIDS-16 is 27.12 
 
Pathogenic Mechanisms of Depression  
The pathogenesis and etiology of depression are not fully understood.  As a result 




not a specific pathological mechanism.  The monoamine hypothesis is the basis of current 
antidepressant treatment.  This hypothesis posits that depression is caused by the 
depletion of monoamines in the brain.  Monoamines are the neurotransmitters serotonin, 
norepinephrine, and dopamine.13   Patients with MDD vary greatly in presentation of the 
disorder, and the development of MDD is based on the interplay of multiple factors.  
These factors include; psychological, biological, genetic, and social.6   Individual patients 
vary greatly in regard to these different factors, and thus there is significant variability in 
treatment outcomes.  Research over the last few decades has focused on using rodent 
animal models and human research to discover pathological mechanisms for MDD.  This 
research has been successful in illuminating several mechanisms for the development of 
depression.  An aspect shared by many of these mechanisms is a stress mediated response 
that causes the display of a depressive phenotype in a vulnerable individual.45   
Psychological stress can be divided into two categories, acute and chronic, with chronic 
having a more deleterious effect on an individual’s psychological and physiological 
functioning.66   Nonetheless, a common etiology between all patients with MDD has not 
been found.45  
In regards to the monoamine hypothesis, research studies in humans have shown 
that decreasing the levels of monoamines in patients with MDD does not worsen 
symptoms of depression and implementing the same procedure on healthy subjects does 
not cause the development of MDD.13   This evidence suggests that depletion of 





One proposed mechanism for the development of MDD is the neurotrophic theory 
of depression.  This theory posits that chronic stress induces low levels of neurotrophic 
factors in the brain which then causes changes to neurogenesis and synaptic plasticity.  
This ultimately results in a depressive phenotype.45   In relation, neurogenesis pertains to 
the development of new neurons, whereas increased synaptic plasticity refers to the 
increase in communication, i.e. synaptic strength, between existing neurons.  Brain-
derived neurotrophic factor (BDNF) belongs to the nerve growth factor (NGF) family of 
neurotrophins and is the most important neurotrophic factor in the brain.45   This 
importance stems from the role BDNF plays in linking neuron differentiation and 
synaptic plasticity.17   The mechanism by which BDNF increases synaptic plasticity is 
known, while the role that BDNF plays on neurogenesis is not.17  However, research 
studies have found that increased neurogenesis in an area of the brain corresponds to 
increased BDNF signaling in that same area.35   The major source of BDNF in the brain is 
the glutamatergic synapse, the predominant excitatory synapse in the brain, which is 
essential for synaptic plasticity and neurogenesis.  BDNF increases synaptic plasticity by 
increasing activity of the postsynaptic ionotropic glutamate receptors, as well as inducing 
signaling pathways of its own by binding its respective postsynaptic receptor.17   
Specifically, the postsynaptic receptors for glutamate are AMPA and NMDA, while the 
postsynaptic receptor for BDNF is the tropomyosin-related kinase receptor (TrkB).17   




synaptic plasticity by causing local changes to dendritic spine formation, protein 
synthesis, and levels of gene transcription.17 
In relation to the development of MDD, there is compelling evidence from rodent 
and human studies that alterations to BDNF concentration in the brain are responsible for 
the anatomical and functional abnormalities seen in MDD.  It has been found that there is 
decreased neurogenesis and synaptic plasticity in the Prefrontal Cortex (PFC) and 
Hippocampus (HIPP) in histopathological studies of depressed patients.45   While on the 
other hand, increased neurogenesis and synaptic plasticity has been observed in certain 
areas of the mesolimbic dopamine system in the depressed brain.  One of these areas 
being the Nucleus Accumbens (NAc).45   Altered connectivity and neuronal loss or gain 
in these brain areas is responsible for some of the key symptoms of MDD.  Moreover, 
chronic stress and subsequent changes to BDNF concentrations in the brain are consistent 
with these findings.  To begin with, serum BDNF concentration in patients suffering from 
MDD is reduced threefold compared to those not suffering from MDD.6   Research 
studies have found strong evidence that stress causes decreased BDNF signaling in the 
HIPP and PFC.35   While in the mesolimbic system, stress increases BDNF levels and 
results in a MDD phenotype.  In relation, post mortem MDD human studies have found 
increased BDNF concentration in the NAc.45   However, it was found that deletion of the 
gene for BDNF in rodents was not sufficient enough to cause a depressive phenotype.  
This evidence suggests that changes to levels of BDNF in the brain may not be the 





There is evidence that increased inflammation due to chronic stress, and 
associated peripheral immune system activation, may be involved in the development of 
MDD.  Research studies have found that continuous activation of the peripheral immune 
system, and related disturbances to leukocyte function and cytokine number, may cause 
MDD in vulnerable individuals.45   However, the precise mechanism of how increased 
inflammation leads to MDD is not fully understood.  The cytokines involved in 
inflammatory mechanisms for MDD are interleukin 1 (IL-1), interleukin 6 (IL-6), and 
tumor necrosis factor alpha (TNF); which are all pro-inflammatory. IL-1 and TNF 
also affect synaptic plasticity.45   The leukocytes involved in this mechanism are 
microglial cells and monocytes.  Microglia are the macrophages of the CNS, but also 
regulate other essential neurobiological processes including neuroplasticity, metabolism, 
and levels of neurotrophic factors.58   Monocytes are leukocytes and thus are produced in 
the bone marrow and either stored in the bone marrow or spleen.  Under normal 
circumstances, circulating monocytes are unable to cross the blood-brain barrier (BBB).45   
Another cell that is crucial in the stress susceptibility response is the astrocyte.  This cell 
provides structural integrity to the BBB and is also responsible for glutamate uptake at 
excitatory synapses.58    
One inflammatory mechanism proposes that chronic stress causes BBB 
breakdown.45   This allows the infiltration of peripheral monocytes into the CNS.  Once 
in the brain, these monocytes release pro-inflammatory cytokines which include IL-1, IL-




microglia.45   Increased microglial activation leads to microglial dysfunction, which 
causes of abnormalities to synaptic plasticity, neurogenesis, neuroprotection, as well as 
the production of more pro-inflammatory cytokines in the brain.58   In addition, chronic 
stress and pro-inflammatory cytokines cause astrocyte dysfunction. As a result, the BBB 
becomes increasingly compromised and glutamate uptake decreases leading to 
excitotoxicity.45   In this mechanism, there is positive feedback that exacerbates the brain 
alterations caused by inflammation.  Furthermore, this mechanism posits that elevated 
levels of pro-inflammatory cytokines are the cause of the anatomical, physiological, and 
behavioral abnormalities seen in MDD. 
There is some evidence to support the inflammatory mechanism for MDD, but not 
enough to deem it the primary cause of depression. To begin with, research studies have 
shown patients suffering from mood disorders exhibit a compromised BBB.45   In 
relation, rodent studies shown that repeated social defeat (RSD), a method used on 
rodents to induce a depression-like phenotype, promotes the infiltration of monocytes 
originating from the periphery into the brain.45   This research suggests that the BBB 
becomes compromised due to stress.  In addition, it has been found in human studies that 
the injection of pro-inflammatory cytokines induces behaviors consistent with 
depression; whereas antidepressant pharmacotherapy brings cytokine levels back to 
baseline.45   In regards to microglial function, it has been shown via positron emission 
tomography (PET), that there is enhanced microglia activation during a major depressive 
episode.45   In postmortem MDD studies, researchers have found decreased expression of 




that the loss of this protein results in astrocyte dysfunction and subsequent BBB 
susceptibility. Also, there is evidence from clinical settings that anti-inflammatory drugs 
can have an antidepressant effect in patients suffering from MDD.45  
Neuroendocrine Mechanism 
Another proposed mechanism for the development of MDD centers around the 
effects that psychological stress has on the neuroendocrine system.  An essential 
component of the neuroendocrine system is the hypothalamic-pituitary-adrenal (HPA) 
axis; as it is the central stress response system in the body.  The end hormone secreted by 
the adrenal gland is cortisol, which is the primary stress hormone.  The HPA axis is 
regulated by feedback loops under normal conditions, in order to ensure that hormone 
levels return to pre-stress levels after the physiological stress response is no longer 
needed.66   In addition, the levels of the neurotransmitter glutamate have seen to be 
affected by stress, as well as cortisol concentration.54   As stated previously, the 
glutamatergic synapse is essential in neuronal remodeling and brain function. 
One mechanism proposes that chronic psychological stress causes over-activation 
of HPA axis which then causes increased release of corticotrophin releasing factor (CRF) 
from the hypothalamus.66   Increased CRF concentration causes increased 
adrenocorticotropic hormone (ACTH) release from the anterior pituitary.  Then, this 
increased ACTH concentration causes increased glucocorticoid release from the adrenal 
cortex.  One of these glucocorticoids is cortisol, the primary stress hormone.66   Elevated 
levels of cortisol cause excitotoxicity to neurons, leading to inhibition of neurogenesis 




axis causes dysregulation of glucocorticoid feedback loops and thus negative feedback 
cannot be achieved.  In turn, this stress mediated reaction continues and its ramifications 
are exacerbated.  In relation to HPA axis overdrive, chronic psychological stress causes 
increased glutamate concentration, by increased release and/or decreased uptake, and in 
turn excitotoxicity.54   This excitotoxicity causes neurodegeneration and altered synaptic 
connections, and contributes the development of MDD.   
There is strong evidence from research studies that support this mechanism.  It is 
known that psychological stress increases serum glucocorticoid concentrations and 
increases in glucocorticoid concentration have been observed in patients suffering from 
MDD.6   It also has been shown that elevated glucocorticoid concentrations may reduce 
the volume of the HIPP; which would alter the function of brain areas related to emotion 
and reward consistent with MDD.45  In rodent studies, CRF oxer-expression induced 
depression-like behaviors and selective deletion of CRF receptors in limbic areas of the 
brain resulted in antidepressant effects.45   In relation to glutamate, studies have found 
higher glutamate concentrations in patients suffering from MDD compared to healthy 
subjects, and that treatment with antidepressant medications can decrease glutamate 
levels in depressed individuals.54   Rodent studies have found evidence that 
administration of corticosterone, the equivalent to cortisol in rodents, induces an increase 
in glutamate concentration in brain areas pertaining to depression.  Specifically, the 





MDD does not appear to be a single gene disorder, however, twin studies show a 
heritability of around 37%.6   There is evidence that epigenetic changes are a risk factor 
for MDD.6   Epigenetic mechanisms for the development of MDD propose that the 
environment, i.e. psychological stress, causes modifications to gene expression which 
results in greater or lesser transcripts of a gene.  These modifications occur post 
translationally and do not modify the DNA sequence.  Some epigenetic modifications 
include DNA methylation and histone acetylation.  DNA methylation involves the 
addition of a methyl group to cytosine of the DNA sequence resulting in decreased 
transcription of a gene.  Histone acetylation involves the addition of an acetyl group to 
histones, which relaxes chromatin and allows greater access for transcription factors to 
bind DNA.6   Histone deacetylation is the reverse reaction of the previous process, and 
thus results in lessor access for transcription factors to bind DNA.  In addition, DNA 
methyltransferase (Dnmt), the enzyme responsible for the addition of a methyl group to 
cytosine, has been shown to play a role in synaptic plasticity and function.45   
An example of an epigenetic mechanism involves psychological stress increasing 
the DNA methylation of the p11 gene sequence, resulting in less p11 expression.61   The 
protein p11 has shown to enhance neuronal signaling and is expressed in brain areas that 
are essential for the development of MDD.  These brain areas include; NAc, PFC, and 
HIPP.61   As a result of decreased p11 protein concentration there is decreased signaling 
from serotonergic neurons in these brain areas.  This decreased serotonin function causes 




There is some evidence from research studies to support the epigenetic 
mechanism of MDD.  Postmortem studies of suicide victims found decreased p11 
expression in the HIPP and amygdala.61  A genetic rat model of depression has shown 
that decreased p11 expression was linked to increased DNA methylation of the p11 gene 
promoter region.61  Furthermore, it was seen that this increased DNA methylation could 
be reversed by treatment with an SSRI, specifically escitalopram.45   Research from 
transfected cell lines have shown that increased expression of p11 increased the levels of 
serotonergic receptors, and subsequently serotonergic signaling.45  From rodent studies, it 
was observed that the increase of monoamines from antidepressant treatment increased 
p11 mRNA levels in the PFC and HIPP.61   
Pharmacotherapy for Depression  
The first use of medication to treatment depression occurred in the 1950s with the 
clinical implementation of MOAIs and TCAs, known as the first-generation 
antidepressants.  In the 1980s, SSRIs and SNRIs, known as the second-generation 
antidepressants, were introduced and became the predominant pharmacotherapy for the 
treatment of depression.27   SSRIs and SNRIs are preferred over MOAIs and TCAs 
because these medications exhibit improved safety and less toxicity in comparison.47  
First and second-generation antidepressants both act by increasing serotonergic 
and/or noradrenergic transmission.  This action is consistent with the monoamine 
hypothesis.  The monoamine hypothesis posits that depression is caused by the depletion 
of serotonin, norepinephrine, and dopamine concentrations in the brain.38   This 




the second being the pharmacological mechanism of action of antidepressants.38   
Reserpine is a plant alkaloid that is known to inhibit vesicular monoamine transporter, 
resulting in monoamine depletion.  In the 1950s, reserpine was being used to treat 
hypertensive vascular disease but it was found that its administration resulted in the 
development of depression in some patients.38   Secondly, the fact that antidepressants act 
by increasing levels of monoamine neurotransmitters provided further evidence to 
support this hypothesis.  However, evidence has emerged that the monoamine hypothesis 
needs to be revised and that the depletion of monoamines is not a sufficient enough 
explanation for the development of MDD.  Rather, it seems that monoamine depletion 





Figure 2. Pharmacological Targets for Antidepressants.  Taken from (O’Donnell, Bies, & Shelton, 
2017).  This diagram illustrates the respective targets of antidepressants.  To begin with, TCAs blocks both 
the serotonin reuptake transporter (SERT) and norepinephrine transporter (NET) located at presynaptic 
terminals.  TCAs can block receptors as well, including the 1 adrenergic receptor (1AR).  MAOIs inhibit 
the enzyme responsible for the catabolism of norepinephrine (NE) and serotonin.  SNRIs block both NET 
and SERT.  SSRIs only block SERT.  The result of each of these pharmacological actions is an increased 





SSRIs: Serotonergic Target 
Fluoxetine, brand name Prozac, was the first SSRI approved by the FDA in 1987 
for the treatment of depression and anxiety disorders.27   Since then, SSRIs have been the 
first-line pharmacotherapy for the treatment of depression, as well as the one of the most 
frequently prescribed medications in United States medicine.60   SSRIs act by boosting 
serotonergic transmission in the brain.  This is achieved by blocking the serotonin 
reuptake transporter (SERT) located on the presynaptic membranes of serotonergic 
neurons.  The selectivity of SSRIs stems from the inhibition of SERT but not 
norepinephrine transporter (NET).47   In turn, more serotonin neurotransmitters are left in 
the synaptic cleft.  Thus, more serotonin is able to bind to postsynaptic serotonin 
receptors.  This ultimately results in greater serotonergic transmission. 
Esketamine: Glutamatergic Target 
Esketamine was approved by the FDA for the treatment of adults with treatment-
resistant depression (TRD) in March 2019, in conjunction with an oral antidepressant.  
TRD applies to patients who have tried at least two antidepressants with no response.8   
Esketamine is the s-enantiomer of ketamine, and exhibits identical mechanism of action, 
but is more potent and safer than ketamine for antidepressant treatment.59   Esketamine 
exhibits greater affinity for the NMDA receptor than racemic ketamine, and is 
administered via nasal spray rather than intravenously.50   Ketamine was first developed 
as an anesthetic in the 1960s, and ketamine is unique as an anesthetic because it produces 
a dissociative psychedelic state, making it a popular drug of abuse.37   Over the past few 




anxiety disorders.  Esketamine treats depression by restoring glutamate and GABA 
systems that are dysfunctional in the MDD brain.68   Specifically, Esketamine is a non-
competitive antagonist of NMDA receptors on GABA interneurons.  This inhibition 
results in disinhibition of glutamate release from presynaptic nerve terminals on 
glutamatergic neurons.  This increased glutamate release results in more AMPA receptor 
binding at the postsynaptic membrane of glutamatergic neurons.68   Depolarization of 
AMPA receptors stimulates voltage-dependent calcium channels (VDCC), which release 
BDNF.  BDNF then binds TrkB and activates downstream signaling pathways.56   There 
is evidence that the antidepressant effect of esketamine is due to increased synaptic 
plasticity and neurogenesis in the HIPP and PFC.56 
 
Figure 3. Ketamine/Esketamine Mechanism of Action.  Taken from (Scheuing, Chiu, Liao, & Chuang, 
2015).  The figure above illustrates the action of ketamine on the postsynaptic membrane of glutamatergic 




The increased glutamate concentration allows for increased AMPA receptor binding on the postsynaptic 
terminal.  AMPA activation stimulates VDCCs, which release BDNF.  BDNF binds to TrkB receptors on 
the postsynaptic terminal and TrkB receptor downstream signaling pathways are activated.  The overall 
effect of these signaling pathways is an increase in synaptic proteins and in turn increased neurogenesis and 
synaptic plasticity.  It should be noted that lines with arrows are stimulatory connections, lines with 
flattened ends are inhibitory connections, and dashed lines are pathways that exhibit reduced activity due to 
ketamine treatment.56 
 
Brexanolone: GABAA Modulating Agent 
Brexanolone was approved by the FDA for the treatment of postpartum 
depression (PPD) in adult women in March 2019.57   Brexanolone is the synthetic form of 
allopregnanolone, which is a metabolite of progesterone and acts as a neurosteroid in the 
brain.  Allopregnanolone is metabolized and released in the brain in response to stress.53   
Allopregnanolone acts as an endogenous positive allosteric modulator of GABAA 
receptors.  Thus, increasing activity of GABAA receptors when GABA is bound.33   This 
mechanism of action is shared by anxiolytic drugs like benzodiazepines.  There is a rapid 
decrease in progesterone and allopregnanolone concentrations following childbirth, 
which makes brexanolone useful in treating PPD in particular.33   PPD affects around 12-
20% of mothers and can last up to 11 years following childbirth.70   Administration of 
Brexanolone synthetically restores neurosteroid concentrations in the brain and 
subsequently restores the GABAergic system.33 
GABA acts as the inhibitory neurotransmitter and plays an essential role in the 
stress response.40   Research studies have shown that patients suffering from MDD 
exhibit reduced concentrations of GABA neurotransmitter and dysfunction in GABAA 
receptors.40   While the GABAergic system is more commonly linked to anxiety 




MDD exhibits high comorbidity with anxiety, with approximately 60% of depressed 





SPECIFIC AIMS AND OBJECTIVES 
The goal of this literature review is to compare 3 different antidepressant 
medications that exhibit different mechanisms of action.  These three medications are 
escitalopram (Lexapro), esketamine (Spravato), and brexanolone (Zulresso).  These 
medications exhibit serotonergic, glutamatergic, and GABA modulating mechanisms of 
action, respectfully.  Escitalopram is being used as the SSRI prototype because some 
meta-analyses have suggested that it exhibits greater efficacy and tolerability than other 
SSRIs.19   Using information from scientific literature, these medications will be 
compared on efficacy, clinical pharmacokinetics, safety, and patient compliance.  From 
these comparisons, a determination will be made as to what mechanism of action shows 
the most promise for future research.  The reason why this review is important is the fact 
that only 50% of patients respond to first-line antidepressant treatment.  For an illness 
with such a high prevalence, economic burden, and comorbidity, there is great need for 




REVIEW OF PHARMACOLOGICAL STUDIES 
Efficacy  
The efficacy of antidepressant treatment is evaluated by using depression 
symptom severity scales to monitor the change in symptoms at various stages of the 
treatment process.  Such scales are used in efficacy trails to define remission.71   Thus, 
the efficacy of antidepressant treatment is determined by the magnitude of decrease in 
depression score.  The two most commonly used depression rating scales in clinical trials 
are the Montgomery-Asberg Depression Rating Scale (MADRS) and the Hamilton 
Depression Rating Scale (HDRS). 
The HDRS, also known as the HAM-D, is a clinician administered depression 
rating scale in which a clinician determines a depression rating by conducting an 
interview with the patient.  It was designed to assess the severity of depressive symptoms 
in the hospital, but it is now the most widely used scale for clinical trials.42   The original 
version has 21 items that encapsulate the symptoms of depression a patient has 
experienced over the course of the past week.  The first 17 items are counted towards the 
total score, which is what is relevant in determining efficacy, and the last four items are 
for greater description about the depressive syndrome.42   Unlike in the MADRS, the 
HAM-D scales weighs different symptoms differently, indicating that some symptoms 
are more important than others.  Some symptoms may have the ability to be rated from 0 
to 4, while other symptoms are only rated 0 to 2.  In clinical trials, a score from 0 to 7 
usually indicates remission.42   Treatment response equates to a greater or equal to 50% 




Item Number Item Score Range 
1 Depressed mood 0 (absent) – 4 (most severe) 
2 Feelings of guilt 0 (absent) – 4 (most severe) 
3 Suicidality 0 (absent) – 4 (most severe) 
4 Insomnia – early 0 (absent) – 2 (most severe) 
5 Insomnia – middle 0 (absent) – 2 (most severe) 
6 Insomnia late 0 (absent) – 2 (most severe) 
7 Work and activities 0 (absent) – 4 (most severe) 
8 Retardation 0 (absent) – 4 (most severe) 
9 Agitation 0 (absent) – 4 (most severe) 
10 Anxiety – psychic 0 (absent) – 4 (most severe) 
11 Anxiety – somatic 0 (absent) – 4 (most severe) 
12 Somatic symptoms – GI 0 (absent) – 2 (most severe) 
13 Somatic symptoms – general 0 (absent) – 2 (most severe) 
14 Genital symptoms 0 (absent) – 2 (most severe) 
15 Hypochondriasis 0 (absent) – 4 (most severe) 
16 Loss of weight 0 (absent) – 4 (most severe) 
17 Insight 0 (absent) – 2 (most severe) 
Table 2. HAM-D17 Items and Scoring. The HAM-D17 contains 17 items that can be scored from 0-4 or 0-
2 depending on the importance of the symptom to depression.  The maximum score is a 63, but most 
outpatients seeking treatment for depression fall between 14 and 25.  A score from 0-7 indicates clinical 
remission.42 
 
The MADRS, like the HAM-D, is a clinician administered depression rating scale 
conducted via interview with the patient.  It was created after the HAM-D and is intended 
to be more sensitive to changes due to antidepressants.42   Unlike the HAM-D, the 
MADRS is unidimensional with a possible score of 0 to 6 for each of the ten items.73   
However, both scales are used in clinical trials and there exists a high level of statistical 
correlation between the two scales.  For example, a score of 7 on the HAM-D is 
approximately 10 on the MADRS while a score of 25 on the MADRS is approximately a 
score of 20 on the HAM-D.42   Treatment response is defined as a greater than 50% 
improvement in total score, and remission equates to a total score of less than or equal to 
10 or 12.73 
Item Number Item Score Range 
1 Apparent sadness 
0 (not present) to 6 (severe) 2 Reported sadness 




4 Reduced sleep 
5 Reduced appetite 
6 Concentration difficulties 
7 Lassitude 
8 Inability to feel 
9 Pessimistic thoughts 
10 Suicidal thoughts 
Table 3. MADRS Items and Scoring.  The MADRS contains 10 items with a possible score of 0 to 6 on 




As of today, esketamine has been approved for TRD.  TRD denotes a history of 
nonresponse to at least two antidepressants.  Thus, published phase III clinical trials, 
clinical trials to evaluate efficacy and safety, have been limited to a subject population 
who exhibit TRD.  However, clinical trials in the broader population of MDD subjects 
are ongoing.  An oral esketamine randomized controlled trial (RCT) is also ongoing in 
the Netherlands.  This study aims to examine efficacy, tolerability, safety, mechanisms of 
action, as well as economic impact of an oral formulation of esketamine.59 
A review of studies on intranasal esketamine spray, completed a meta-analysis of 
4 RCTs in order to examine the efficacy, tolerability, and safety of esketamine in treating 
TRD.69   The participants in this study had TRD.  In addition, these RCTs randomized 
subjects into an esketamine nasal spray and oral antidepressant group or a placebo nasal 
spray and oral antidepressant group.  Of the 4 RCTs, trial duration lasted 28 days for 3 
and 8 days for 1.  Administration of the nasal spray was completed twice weekly by 
participants at medical facilities.  Results from this meta-analysis showed that intranasal 
esketamine treatment exhibited significantly greater treatment response and remission 




MADRS total score of  50% and remission equated to MADRS total score that is 12 
(or 10 in 1 RCT).69   The esketamine treatment group demonstrated the following 
response percentages; 50.0% at hour 2, 21.0% at 24 hours, and 58.7% at day 28.69   The 
placebo spray group demonstrated the following response percentages; 18.2% at hour 2, 
21.0% at 24 hours, 43.0% at 28 days.69   The esketamine treatment group demonstrated 
the following remission percentages; 23.5% at hour 2, 30.4% at hour 24, and 42.3% at 28 
days.69  The placebo spray group demonstrated the following remission percentages; 
3.0% at hour 2, 3.8% at 24 hours, and 30.7% at 28 days.69  This showed that esketamine 
was superior to conventional antidepressant treatment for treatment resistant depression 
therapy.  In addition, esketamine showed rapid efficacy.  The esketamine treatment group 
showed significantly greater response and remission starting at 2 hours and peaking at 24 
hours following administration in comparison to placebo.69   Through meta-analysis, the 
rapid antidepressant effects of esketamine intranasal spray has been shown to be superior 
to intravenous (IV) ketamine infusion.  A single IV ketamine infusion has been shown to 
have a significant depression reduction beginning at 40 min from administration, peaking 
at 24 hours from administration, and losing significant antidepressant superiority at 10-12 
days after administration.69 
In one phase III clinical trial, which was included in the systematic review just 
mentioned, 197 participants completed a 28-day treatment period receiving either a 
esketamine spray and antidepressant treatment or a placebo spray and antidepressant 
treatment.50   These participants exhibited moderate to severe depression with a history of 




antidepressant during the treatment phase.  During the 28-day treatment period, 
participants self-administered the esketamine spray, or placebo spray, twice weekly for a 
total of 8 times.  The oral antidepressant was taken daily.50   Efficacy was determined by 
mean MADRS score decrease from baseline to day 28.  The esketamine treatment group 
showed significantly greater improvement in MADRS score than the placebo spray 
group.  The secondary efficacy endpoint of this study was the mean MADRS score 
decrease 24 hours after first administration of nasal spray.  At this marker, the esketamine 
treatment group exhibited a clinically meaningful treatment difference, but not a 
statistically significant difference, compared to the placebo group which suggests a rapid 





Figure 4. Change in MADRS score in 4-week esketamine TRD trial.  Taken from (Popova, et al., 2019).  
This graph shows the least square mean change in MADRS score over 4-week treatment phase in double-
blind treatment phase of a randomized controlled trial of esketamine nasal spray for treatment-resistant 
depression.  The greater the negative change in MADRS score, the greater the improvement of MDD 
symptoms.  The difference between the esketamine receiving group and placebo nasal spray group was 
statistically significant at day 28 with a p value of p=0.020.50 
 
An additional phase III randomized withdrawal study that was conducted in order 
to evaluate the long-term efficacy and tolerability of intranasal esketamine for TRD.11   
455 patients entered a 16-week optimization phase in which all patients received 
esketamine nasal spray in conjunction with an oral antidepressant.  The oral 
antidepressants used were; duloxetine, venlafaxine, escitalopram, or sertraline.11   




optimization phase, were randomized into the variable duration maintenance phase.  The 
trial, in its entirety, was conducted from October 2015 to February 2018.11   Patients 
either continued with esketamine nasal spray and an oral antidepressant or transitioned to 
placebo nasal spray and an oral antidepressant.  The primary efficacy end point was time 
to relapse. In this study, relapse was defined as a MADRS total score of 22 or higher for 
2 consecutive assessments separated by 5 to 15 days.  Relapse was also defined as patient 
hospitalization for worsening depression, suicide attempt, suicide prevention or 
completed suicide.11   Of the 176 patients in stable remission entering the maintenance 
phase, 26.7% in the esketamine group experienced a relapse event and 45.3% in the 
placebo group experienced a relapse event.11   Of the 121 patients in stable response 
entering the maintenance phase, 25.7% experienced relapse and 57.6% in placebo group 
experienced relapse.11  Esketamine delayed risk of relapse by 51% in the stable remission 
group and delayed risk of relapse by 70% in the stable response group.11  Esketamine and 
antidepressant treatment demonstrated significant and clinically meaningful superiority 






Figure 5.  Time to relapse in esketamine long-term trial.  Taken from (Daly, et al., 2018).  This graph 
shows the percentage of patients without relapse in Esketamine nasal spray and oral antidepressant group 
vs. oral antidepressant and placebo nasal spray group in patients who achieved stable remission:  During 




Brexanolone, the synthetic formulation of the neurosteroid allopregnanolone, is 
approved for the treatment of PPD.  Given this indication, the clinical use and clinical 
trial population for brexanolone is exclusive to adult women who have given birth.  
However, phase III clinical trials for another positive allosteric modulator of GABAA 
receptors are currently ongoing.  This new GABA modulating agent, SAGE-217, is made 
by the same pharmaceutical company as brexanolone and is hoped to be efficacious in the 
general adult MDD population.51   This experimental drug is similar in pharmacological 
make up. 
A meta-analysis of RCTs used the data from 3 RCTs from 2 clinical trials in order 
to examine the efficacy, tolerability, and safety of IV brexanolone infusion for the 
treatment of PPD.70,44,31   These RCTs were phase III clinical trials.  In total, there were 




IV brexanolone infusion and 111 receiving placebo IV infusion.70   Efficacy end points in 
the RCTs were as follows; treatment response indicated a  50% reduction in total HAM-
D score and remission indicated a HAM-D total score  7.70  The IV brexanolone or 
placebo infusion was administered over a period of 60 hours and the trials had durations 
of 30 days.44,31  Brexanolone exhibited significantly greater treatment response compared 
to placebo with treatment response beginning 2 hours after start of infusion, peaking at 36 
hours into infusion, and lasting 7 days after infusion start.70  Similarly, brexanolone 
exhibited significantly greater remission than placebo beginning 24 hours after infusion 
start, peaking at 60 hours, and lasting until 72 hours after start of infusion.70 The meta-
analysis showed that IV brexanolone infusion for women with moderate to severe PPD 
was significantly superior to placebo in regards to antidepressant efficacy.  This review 





Figure 6. Change in HAM-D score in brexanolone trial.  Taken from (Meltzer-Brody, et al. 2018).  
Percentage Change from baseline in mean HAM-D total score.  BRX90 indicates 90 g/kg per h 
brexanolone infusion.  The larger the decrease in the graph the larger the decrease in mean HAM-D total 
score.  It was seen, that the proportion of patients achieving treatment response was significantly higher for 
the BRX90 group at all time intervals from 48 hours to day 7.  The proportion of patients achieving 
remission was higher for the BRX90 group, compared to placebo, from 8 h to day 7.  The proportion of 
patients achieving remission was statistically significant at multiple time intervals, from 8 h to day 7, for 
the BRX90 group.  One such time interval was at 60 h, i.e. the end of infusion.44 
 
A meta-analysis that aimed to compare the efficacy of brexanolone injection to 
SSRI in treatment of PDD, in order to determine if brexanolone demonstrated superiority 
in treating the condition.9   This systematic literature review pooled data from 26 studies 
that implemented pharmacologic action in order to treat PPD.9   The researchers used a 
matching-adjusted indirect comparisons technique in order to compare brexanolone 
versus SSRI treated PPD patients at various time intervals.  At day 3, brexanolone 
demonstrated an average 13.47 greater reduction in HAM-D score than SSRI.  At week 4, 
brexanolone demonstrated an average 8.41 greater reduction in HAM-D score than SSRI.  
From weeks 4-18, brexanolone demonstrated an average 4.05 greater reduction in HAM-
D score than SSRI.9   At the first two time intervals, brexanolone demonstrated a 
significant greater reduction in HAM-D score in matching-adjusted indirect comparisons. 
A phase 2 clinical trial that was conducted in order to determine whether SAGE-
217, an oral positive allosteric modulator of GABAA receptors was efficacious and safe 
for the treatment of MDD.24   A total of 89 patients underwent a treatment phase of 15 
days with 45 patients receiving SAGE-217 daily and 44 receiving placebo daily.24   
Efficacy was determined by decrease in HAM-D score.  The primary efficacy endpoint 
was the change in HAM-D score from baseline to day 15.  The secondary efficacy end 




SAGE-217 exhibited a statistically significant larger decrease in HAM-D score at all end 
points.  This trial provided evidence that SAGE-217 exhibits efficacy in treating MDD 
but more research is being done in order to confirm this. 
Escitalopram 
Escitalopram was released in August 2002 as an updated approach to SSRI 
treatment due to increased selectivity.10   Escitalopram is the pure S-enantiomer of 
racemic citalopram, an older SSRI, and it is 40-fold more potent than the R-enantiomer of 
racemic citalopram for the inhibition of SERT.  Escitalopram differs from citalopram in 
another pharmacological characteristic, in that it exhibits virtually no affinity for other 
receptors.7 
A systematic review of escitalopram treatment of MDD in the primary care 
setting conducted a meta-analysis in order to evaluate the efficacy and safety of 
esictalopram.10   Included in this review, was a phase III clinical trial conducted in 
primary care centers in Canada, Europe, and United Kingdom in order to demonstrate 
efficacy and safety.10   This clinical trial included a total of 380 patients with moderate to 
severe depression, 189 received a placebo pill and 191 received escitalopram 10mg/day.10  
Efficacy was determined by decrease in MADRS score.  The escitalopram treatment 
group demonstrated significantly higher rates of treatment response and remission at 
week 8.  The decrease in MADRS score for the escitalopram group became significantly 
greater than placebo group at week 2.10   This suggests the antidepressant response for 





Figure 7.  Change in MADRS score in 8-week Escitalopram trial.  Taken from (Culpepper, 2002).  
Change in MADRS score of Placebo treatment vs. Escitalopram 10mg/day treatment for 8-week treatment 
period.  The change in MADRS score became significantly different for Escitalopram treatment group, in 
comparison to placebo treatment group, at week 2 and continued until end of treatment phase.10 
 
A systematic review of phase III clinical trials on Chinese outpatients was 
conducted in order to determine efficacy and safety of escitalopram monotherapy for 
MDD.36   This review preformed a meta-analysis of 4 Chinese RCTs that used 
escitalopram to treat MDD.  A total of 640 outpatients with a HAM-D17 score of 18 
underwent treatment across 4 RCTs that exhibited similar methodology.  Patients were 
treated with either escitalopram/citalopram or placebo for a period of 6 weeks.36   
Efficacy was determined by change in total HAMD17 score from baseline to end of study.  




was defined as a HAMD score of 7.  Researchers of this meta-analysis divided patients 
into different subgroups in order to make more interpretations from the RCT data. These 
subgroups included severity of MDD and number of depressive episodes.  Overall the 
treatment response and remission rates following the 6-week treatment period were 
68.4% and 46.4% respectively, for the escitalopram and placebo receiving groups.36   
There were significantly different treatment response and remission rates between 
severity subgroups.  The treatment response rates were 76.9%, 63.7%, and 63.0% for the 
mild, moderate, and moderate-severe MDD severity subgroups.36   The remission rates 
were 64.0%, 41.6%, and 27.2% for the mild, moderate, and moderate-severe MDD 
severity subgroups.36 
Pharmacokinetics and Safety  
Esketamine 
Esketamine is administered by a medical professional twice per week, once per 
week, or once every two weeks.  Treatment intervals and dosages are dependent on 
patient efficacy and tolerability.  Esketamine is administered as a nasal spray and is 
absorbed via inhalation.29   Inhalational administration is better suited for chronic therapy 
because it circumvents the need of sterile venipuncture, while still maintaining rapid 
absorption.30 It should be noted that oral administration is the best suited form for chronic 
therapy.  Esketamine reaches maximum plasma concentration (Cmax) in 20 to 40 minutes 
following inhalation.  The mean absolute bioavailability of intranasal esketamine, i.e. the 
fraction of the dose that gets into the blood stream, is approximately 48%.29   Esketamine 




enzymes primarily responsible for this nonrenal clearance are cytochrome P450 (CYP) 
enzymes, specifically CYP2B6 and CYP3A4.  Noresketamine is then further metabolized 
via phase I and/or phase II biotransformation.30   These enzymes act in the liver and thus 
patients with moderate hepatic impairment should be monitored for a longer period of 
time following administration.  Esketamine is not recommended for patients with severe 
hepatic impairment.  In regards to elimination, esketamine exhibits a mean terminal half-
life (t1/2) that ranges from 7 to 12 hours following administration.29   This elimination of 
esketamine from plasma is biphasic, with a rapid decline occurring at 2 to 4 hours after 
administration.30  
Adverse reactions associated with esketamine treatment include; sedation or loss 
of consciousness, dissociation, increase in blood pressure, cognitive impairment, 
ulcerative or interstitial cystitis, and embryo-fetal toxicity.29   Most of these side effects 
are transient and resolve the same day of treatment.  In addition, esketamine is a schedule 
III controlled substance and is at risk for drug abuse or dependence.  Long term ketamine 
abuse can cause physical dependence and subsequent withdrawal.29   In a cross-sectional 
study of lifetime ketamine users in Australia, 1/5 reported developing a tolerance.15   
However, it should be noted that no withdrawal symptoms or signs of abuse were 
reported in the 4 week esketamine clinical trials submitted to the FDA.29  It was seen 
from clinical studies, included in the FDA approval, that cognitive performance 
decreased 40 minutes post dose but returned to baseline at 2 hours post administration.29   
Long term cognitive performance deficits have been reported with ketamine abuse, but 




past one year.  In regards to ulcerative or interstitial cystitis, long term illegal use of 
ketamine can cause these conditions, but no cases of these conditions have been found in 
esketamine treatment.  These conditions may occur in future esketamine research.   Due 
to these risks, esketamine is only dispensed in healthcare settings and patients are 
monitored for at least 2 hours following treatment.29 
Esketamine is known to interact with central nervous system depressants, 
psychostimulants, and MAOIs.  Concomitant administration with central nervous system 
depressants, such as benzodiazepines, can increase sedation.  Psychostimulants, such as 
amphetamines, and MAOIs can exacerbate hypertension that occurs with esketamine 
treatment.29   Esketamine demonstrates mild to moderate induction of CYP2B6 and 
CYP3A4 enzymes but, via drug interaction studies, this induction does not result in any 
clinically significant drug-drug interactions.30 
A systematic review of 4 esketamine RCTs previously referenced evaluated safety 
of intranasal esketamine.69  Across the 4 RCTs, the adverse events that were significantly 
more frequent in the esketamine and antidepressant treatment group compared to the 
placebo and antidepressant group included: blurred vision, dizziness, dizziness postural, 
somnolence, sedation, vertigo, nausea, dissociation, dissociative disorder, feeling 
abnormal, feeling drunk, hypoesthesia, hypoesthesia oral, lethargy, paresthesia, throat 
irritation, and vomiting.69  Dissociative side effects were mild and transient.  Dissociative 
side effects peaked at 30 to 40 minutes following administration and usually resolved by 




Esketamine treatment can cause an increase in blood pressure and is 
contraindicated for patients in which an increase in blood pressure can cause serious 
health risk.29   A systematic review was conducted, using patients from 6 clinical trials, in 
order to evaluate the cardiac safety associated from esketamine nasal spray.16   In total, 
this review included 1709 esketamine-treated adults and 486 placebo-treated patients.16  
A transient increase in blood pressure and heart rate was observed in the esketamine 
treated patients.  These changes reached maximum levels 40 minutes after administration 
and returned to baseline approximately 1.5 hours post dose.  Additionally, no clinically 
relevant electrocardiogram changes were observed.16 
A phase III randomized withdrawal study, referenced above, was conducted in 
order to evaluate the long-term efficacy and tolerability of intranasal esketamine for 
TRD.11   The 5 most common adverse events in the esketamine and antidepressant group 
were dissociation, vertigo, dizziness, dysgeusia, and somnolence.11   These adverse 
events generally resolved the same day as treatment.  The magnitude of these symptoms 
decreased after the induction phase and was relatively low during the optimization and 
maintenance phase.11   6 serious adverse reactions occurred, for the esketamine and 
antidepressant group in the induction phase.  These reactions were; disorientation, 
hypothermia, lacunar stroke, sedation, and simple partial seizure.11   No such events 
occurred in the optimization or maintenance phase.  There were no symptoms of 
psychosis and no cases of respiratory depression or interstitial cystitis were observed.  
Additionally, there were no reports of suicidal ideation or suicidal behavior in the 




of esketamine misuse or abuse.  Additionally, no evidence of withdrawal syndrome was 
demonstrated after cessation of esketamine treatment.11   Ultimately, no new safety 
concerns were demonstrated in this long-term esketamine study, in comparison to the 
short-term clinical studies previously referenced. 
Brexanolone 
Brexanolone is a class IV controlled substance and a healthcare provider is 
present throughout the duration of treatment in order to monitor the patient and intervene 
if necessary.  Brexanolone is administered via continuous intravenous infusion over a 
period of 60 hours.53   Brexanolone is administered in a stepped IV infusion in which 
dosing is up-titrated then down-titrated at various intervals during the 60-hour infusion.  
Brexanolone exhibits 99% plasma protein binding and this binding is independent of 
plasma concentration.34   Brexanolone demonstrates non-renal clearance and is 
metabolized by phase II biotransformation enzymes in the liver.  This metabolism yields 
three major metabolites, which are not pharmacologically active and do not contribute to 
efficacy.53   The elimination half-life of brexanolone is approximately 9 hours.53   
Brexanolone is excreted primarily as metabolites in feces or urine.  After administration, 
47% of brexanolone was recovered in feces, primarily as metabolites, and 42% was 
recovered in urine with 99% as metabolites.53   Studies included in the FDA approval 
show that renal impairment and hepatic impairment did not result in clinically significant 
differences in the pharmacokinetics or tolerability of brexanolone.53   
The adverse effects related to brexanolone treatment are excessive sedation/loss 




effects are transient, and in results submitted to the FDA, all patients with sedation or 
altered state of consciousness recovered from symptoms following dose interruption.53   
There is also risk of fetal harm during pregnancies which is based on findings from 
animal studies and other GABAA modulating drugs.  However, there is no available 
brexanolone study data on the drug-associated risk of fetal outcomes.53   As a controlled 
substance brexanolone poses a risk for abuse and dependence.  A human abuse potential 
study found that the therapeutic dose of brexanolone scored similarly to placebo on 
subjective drug abuse likelihood measures.  In regards to this study, 3% of patients 
receiving the therapeutic dose of brexanolone reported euphoria, while 13% of patients 
receiving 3 times the therapeutic dose of brexanolone reported euphoria.53   Physical 
dependence was unable to be studied in current clinical trials.   
Brexanolone exhibits drug interactions with CNS depressants and antidepressants.  
Concomitant use of brexanolone and these drugs can exacerbate the sedation related 
effects of treatment.53   In addition, brexanolone is prone to protein binding reactions 
given its high plasma protein binding.34   
A systematic review of brexanolone clinical trials previously referenced evaluated 
the safety of IV brexanolone via meta-analysis.70   This meta-analysis of 3 RCTs showed 
that the rates of adverse events between brexanolone and placebo treatment groups were 
not significantly different.  Additionally, the discontinuation rate due to intolerability 
between treatment groups was similar.70   
Another systematic review of brexanolone performed a meta-analysis on the same 




in the brexanolone IV infusion group were somnolence, dizziness, and headache.34   A 
small percentage of patients receiving brexanolone IV infusion, 4%, required cessation of 
treatment due to loss of consciousness.  Researchers attributed the transient sedation and 
loss of consciousness symptoms to infusion rate.34   
A previously referenced phase II clinical trial of SAGE-217, which is a GABAA 
positive modulator that was administered daily as an oral pill, evaluated the efficacy and 
safety of this experimental drug.24   The adverse events that occurred in at least 5% of the 
SAGE-217 treatment group were; dizziness, headache, nausea, and somnolence.24   One 
patient in the SAGE-217 treatment group reported euphoria as an adverse event, which 
indicates a possible risk for recreational abuse. 
Escitalopram 
Escitalopram is administered once daily in the form of an oral tablet, at a dosage 
of either 10 mg or 20 mg.  Escitalopram is absorbed orally and reaches a maximum 
plasma concentration in approximately 5 hours.1   From the start of treatment, 
escitalopram reaches steady-state concentration in 7-10 days.  Additionally, this SSRI 
exhibits relatively low protein binding, at around 56%, and is unlikely to interact with 
high protein binding drugs.1   Escitalopram is metabolized via biotransformation I 
pathways, specifically CYP2C19, CYP2D6, and CYP3A4 isoenzymes in the liver.  These 
reactions yield the metabolites S-demethylcitalopram (S-DCT) and S-
didemethylcitalopram (S-DDCT).52   S-DCT and S-DDCT are significantly less potent 
and exhibit significantly less target receptor affinity, and in turn do not contribute to 




significantly lower plasma concentrations. At steady state, the concentration of 
escitalopram is 3 times greater than S-DCT, while S-DDCT is below a quantifiable 
concentration.52   The elimination half-life of escitalopram is around 27-32 hours with 
minimal renal clearance.1   The percentage of escitalopram that is cleared by the kidneys 
following oral administration is approximately 7%.1  
The most common adverse reactions from escitalopram treatment are; insomnia, 
ejaculation disorder, nausea, diaphoresis, fatigue/somnolence, decreased libido, and 
anogasmia.1   In clinical trials submitted to the FDA for drug approval, these adverse 
events occurred at an incidence greater than 5% and at least twice the incidence rate in 
comparison to placebo.1  Other potential side effects that were gathered from the 
premarketing evaluation of escitalopram include: hypertension, palpitation, light-
headedness, migraine, abdominal cramp, heartburn, gastroenteritis, allergy, chest pain, 
fever, hot flushes, pain in limb, increased weight, arthralgia, jaw stiffness, appetite 
increase, impaired concentration, irritability, menstrual cramps, menstrual disorder, 
bronchitis, coughing, nasal congestion, sinus congestion, sinus headache, rash, blurred 
vision, tinnitus, urinary frequency, and urinary tract infection.1  The respective placebo-
controlled trials included 1428 escitalopram treated patients with an evaluation period up 
to one year.  Additionally, these events occurred at a rate 1% in comparison to placebo.1   
Post-marketing research demonstrates additional adverse reactions but the frequency of 
these reactions was unable to estimated, and in turn a causal relationship with drug 




Escitalopram treatment is associated with more severe health risks.  It should be 
noted, that these conditions are less common than the adverse reactions listed above.  
These include; worsening symptoms of MDD and suicidality in the early stages of 
treatment, Serotonin Syndrome, withdrawal due to antidepressant discontinuation 
syndrome, hyponatremia, abnormal bleeding, activation of mania, seizures, impaired 
cognitive/motor performance, and Angle Closure Glaucoma.1   From a pooled analysis of 
295 short-term clinical trials involving various antidepressants, an increased risk of 
suicidal ideation and suicidality was seen in children, adolescents, and young adults (ages 
18-24) at early stages of treatment.1  A risk of worsening symptoms of MDD was 
exhibited across all ages groups at early stages of treatment.  Serotonin syndrome is a 
condition caused by excessive serotonergic activity.  This can occur from SSRI 
monotherapy or interactions between serotonergic agents.  This condition is rare and can 
be life-threatening, but most cases are mild.28   Serotonin syndrome can manifest in 
autonomic instability, altered mental status, neuromuscular symptoms, seizures, and GI 
symptoms.1   Additionally, withdrawal symptoms have been reported after abrupt 
discontinuation of escitalopram, as with other SSRIs.  The most common withdrawal 
symptoms include; insomnia, nausea, vertigo, light-headedness, electric shock-like 
sensations, and hyperarousal.   Tapering of dose is recommended when terminating 
treatment in order to avoid withdrawal.26   There is an association between drugs that 
modulate serotonergic activity and gastrointestinal bleeding, and thus SSRIs can increase 




Escitalopram can interact with a large number of drugs.  Concomitant use of 
escitalopram with SSRIs, SNRIs, Triptans, MAOIs, TCAs, and other serotonergic agents 
is not recommended due to increased risk of Serotonin Syndrome.1   Alcohol can 
exacerbate deficits in cognitive and motor skills from escitalopram.1   Drugs that exhibit 
anticoagulant properties, like NSAIDS, Aspirin, and Warfarin, increase the risk of 
abnormal bleeding.1  However, the inhibitory effects of escitalopram on CYP isoenzymes 
and P-glycoprotein are clinically negligible and are unlikely to cause drug-drug 
interactions.52  
A systematic review, referenced above, of 4 Chinese RCTs studied the efficacy 
and safety of escitalopram.36   The 4 RCTs implemented a short-term treatment period of 
6-weeks.   The adverse events that occurred at an incidence 4% were nausea, dry mouth, 
somnolence, and fatigue.36   These adverse events were described as mild or moderate, 
and no serious adverse events were observed. 
A systematic review of efficacy, safety, and patient acceptability of escitalopram 
was conducted to compare escitalopram to other antidepressants.32   This review included 
a meta-analysis, of placebo-controlled and comparison trials, that studied the patient 
acceptability of 12 antidepressants drugs, one being escitalopram.  Acceptability in this 
analysis was defined as persistence of drug administration for the 8-week treatment 
period.32   Escitalopram exhibited the highest patient acceptability and the lowest 
discontinuation rate due to adverse events.  The other antidepressants included in this 
analysis were; sertraline, mirtazapine, venlafaxine, citalopram, bupropion, fluoxetine, 




A RCT was conducted in order to investigate the long-term efficacy and 
tolerability of escitalopram in treating MDD.64   590 Patients were transitioned to this 45-
week clinical study after an 8-week RCT, which made the total treatment period a little 
over a year.64   The most common adverse events observed in this study were headache, 
back pain, rhinitis, upper respiratory tract infection, and nausea.64   These adverse 
reactions occurred at an incidence ranging from 11%-17%, and it was seen that no new 
adverse reactions emerged after the initial 8-week RCT.64   
Another systematic review of escitalopram was conducted in order to study the 
cardiac safety of escitalopram.62   This review utilized data from numerous placebo-
controlled studies with a total of 3298 escitalopram receiving patients.  The studies were 
conducted in short-term (8-12 week) or long-term (24-week) intervals.62   The short-term 
and long-term studies garnered similar results.  It was seen that there was a statistically 
significant difference in heart rate compared to placebo, with escitalopram treated 
patients exhibiting a 2-beats per minute decrease in heart rate.62   No clinically significant 
effects from escitalopram treatment were observed in electrocardiogram values, blood 
pressure, or cardiac adverse events.62 
Additionally, a systematic review was conducted in order to analyze the 
relationship between suicidality and antidepressant treatment.49   This publication 
included a meta-analysis of over 130 short-term studies.  Analysis of data from short term 
placebo-controlled studies showed an increase in risk of suicide attempts and suicidal 
ideation in younger patients, whereas a decrease in these areas was found in elderly 




stages of antidepressant treatment.  However, it was noted that studies regarding 
suicidality and antidepressants have many limitations and confounds, and thus the link 
between the two is still unclear.49  
A systematic review of escitalopram treatment in adult patients with MDD and 
anxiety disorders was conducted to investigate the relationship between suicidality and 
treatment with this SSRI.48   This study reviewed all placebo-controlled and relapse 
prevention trials of escitalopram for the treatment of MDD and anxiety disorders.  
Researchers analyzed for events indicative of suicidality which included; fatal suicide, 
non-fatal self-harm, and suicidal thoughts.  There was no significant difference in such 
events between escitalopram (n=2277) and placebo (n=1814) receiving patients.48   
Escitalopram was superior in efficacy in regards to lowering suicidal thoughts, in 
comparison to placebo, from weeks 1 through end of treatment.48   This analysis found no 
evidence that escitalopram provoked suicidality. 
A systematic review was conducted in order to research antidepressant 
discontinuation syndrome.26   This review implemented a comprehensive literature search 
and compiled data from 40 controlled trials, 38 cohort studies and retrospective analyses, 
and 271 case reports.26   The subjects of these studies were all over the age of 18.  This 
analysis found that escitalopram demonstrates a moderate risk of antidepressant 
discontinuation syndrome, compared to other antidepressants, with withdrawal occurring 
in 20% of subjects who abruptly ceased treatment.26   
A preliminary study was conducted to investigate the antidepressant 




25 outpatients who stopped taking escitalopram.  Antidepressant discontinuation 
syndrome occurred in 14 out of the 25 patients.67   The most common symptoms 







Depression is the leading cause of disability in the world, with around 17 million 
adults in the United States alone having experienced at last one episode of MDD.26   
Depression exhibits high somatic and psychological comorbidity as well.  The illness can 
cause severe detriment to one’s social and professional functioning; and consequently, is 
associated with significant economic burden.  Depression is an incredibly complex illness 
in regards to screening, etiology, and treatment.  There are numerous proposed 
pathological mechanisms of depression.  Some different types of pathological 
mechanisms include; a neurotrophic mechanism, an inflammation mechanism, a 
neuroendocrine mechanism, and an epigenetic mechanism.  There is a great need for new 
or augmented pharmacological treatments, as only 50% of patients respond to first-line 
antidepressants.66   Additionally, 33% of the patients do not achieve remission of 
symptoms after multiple antidepressant regimens.50   Since the 1950s, pharmacotherapy 
of depression has been based on monoaminergic transmission.  Current antidepressants 
are effective and tolerated for a great deal of the MDD patient population, but there are 
still millions who are left without relief of their symptoms.  Research over the last few 
decades has illuminated that the monoamine hypothesis is not an adequate explanation 
for the cause of MDD as many other potential etiologies have been discovered. This 
reinforces the value of having pharmacotherapies with different mechanisms of action.  
In 2019 the FDA approved the use of two antidepressants, with novel mechanisms of 




brexanolone is approved for PPD.  These medications are effective and tolerated in these 
populations.  The aim of this literature review was to compare 3 antidepressants with 
different mechanisms of action; escitalopram, esketamine, and brexanolone.  This 
comparison was made in order to provide insight on which mechanism warrants greater 
focus in terms of future research.  There is promise that these novel mechanisms of 
action, glutamatergic and GABAergic, may prove to be effective in the larger MDD 
population.  If so, more patients can find relief from this illness. 
The onset of efficacy favors esketamine and brexanolone compared to 
escitalopram.  Brexanolone became significantly superior, in antidepressant efficacy, to 
placebo at hour 2 of treatment.  In indirect comparison with SSRI for PPD, brexanolone 
exhibited a 13.47 greater reduction in HAM-D score at day 3 of treatment.9   Similarly, 
esketamine nasal spray and antidepressant treatment became significantly superior, in 
antidepressant efficacy, to placebo nasal spray and antidepressant treatment at hour 2 of 
treatment.  Esketamine and antidepressant treatment exhibited 23.5% remission at hour 2, 
while placebo and antidepressant exhibited 3.0% remission at hour 2.69   Escitalopram is 
slower to reach statistically significant antidepressant efficacy, not occurring until week 2 
in one meta-analysis.10   The limitation of this comparison is that brexanolone and 
esketamine were studied in depression subtype populations, respectively PPD and TRD.   
It was seen that in these depression subtypes, brexanolone and esketamine were 
significantly superior in magnitude of antidepressant efficacy, in comparison to SSRIs.  
The comparison in antidepressant efficacy between esketamine and SSRIs was built in to 




antidepressant treatment demonstrated 42.3% remission at day 28, while placebo and 
antidepressant treatment demonstrated 30.7% remission at day 28.69   For brexanolone, 
this comparison was done via meta-analysis of PPD studies.9   In comparison to SSRIs, 
Brexanolone demonstrated an 8.41 greater reduction in HAM-D score at week 4 and a 
4.05 greater reduction in HAM-D score during weeks 4-18.9  The experimental drug 
SAGE-217, a GABAA receptor modulator, has shown antidepressant efficacy for MDD 
patients in phase II clinical studies but more research is needed to be done in order to 
confirm this.  For long-term antidepressant efficacy, esketamine was seen to be superior 
to SSRIs in patients with TRD.  In a long-term clinical study, 25.7% of stable response 
patients experienced relapse while undergoing esketamine and antidepressant treatment, 
while 57.6% of stable response patients experienced relapse while undergoing placebo 
and antidepressant treatment.11   No long-term studies of brexanolone for PPD treatment 
are available, which may be due in part to administration method.   
Brexanolone exhibits the most favorable safety profile, followed by esketamine, 
and lastly escitalopram.  Brexanolone demonstrated the mildest adverse events due to 
treatment.  The adverse events related to brexanolone treatment were; sedation/loss of 
consciousness and symptoms relating to altered mental state during the infusion period.53   
Brexanolone exhibits a relatively low number of drug interactions.  These interactions 
being with CNS depressants, antidepressants, and high protein binding drugs.53   Long 
term safety studies have not been performed on brexanolone.  Esketamine treatment 
exhibits a slightly more severe side effect profile than brexanolone.  The adverse events 




in blood pressure.29   These events resolve around 2 hours post administration.  The one 
long term clinical study on esketamine found no additional adverse events from long-
term treatment and no signs of abuse or dependence.11   Esketamine has a similar drug 
interaction profile to brexanolone.  These being; central nervous system depressants, 
psychostimulants, and MAOIs.  These interactions can exacerbate the blood pressure 
increase and sedation side effects of esketamine treatment.29   Escitalopram demonstrates 
the most severe and wide-ranging side effect profile out of these 3 medications.  The 
severity of these side effects commonly dissipates as treatment progresses.  Additionally, 
escitalopram is associated with more severe health risks.  Some of these include; 
suicidality, antidepressant discontinuation syndrome, serotonin syndrome, abnormal 
bleeding, and seizures.1   Escitalopram can interact with a large number of drugs as well.  
These drug interactions can increase risk to severe reactions.  For example, serotonergic 
agents increase the risk of serotonin syndrome and anticoagulating agents increase the 
risk of abnormal bleeding.1   A limiting factor in this comparison is the fact that the safety 
of escitalopram has been studied for a far longer period of time than esketamine and 
brexanolone.  This suggests that more severe risks of treatment with esketamine and 
brexanolone may emerge in future research. 
In terms of abuse potential, escitalopram is the most favorable. Followed by 
brexanolone and esketamine is the least favorable.  Escitalopram is not scheduled as a 
controlled substance.1   However, physical dependence can manifest from escitalopram 
treatment and subsequent withdrawal after cessation can occur.67   As a class IV 




doses brexanolone was similar to placebo on subjective drug abuse likelihood measures.1   
Esketamine poses the largest risk in drug abuse potential.  Ketamine is a known drug of 
abuse and long-term abuse has been linked to ulcerative/interstitial cystitis and cognitive 
impairment.29   Consequently, esketamine is only administered in health care settings.  
However, as a nasal spray it could be administered by the patient.  Evidence of 
withdrawal syndrome has not been demonstrated in clinical studies of esketamine.   
Patient compliance in antidepressant treatment refers to adherence to drug 
administration frequency and dosing.  Poor adherence to antidepressant treatment is 
common.  In a study aimed to identify the aspects of dosing in patients with MDD who 
were prescribed escitalopram once daily, it was seen, over an average treatment period of 
210 days, that 17.9% of patients did not take the prescribed medication and 31% did not 
take the correct dosage.65   The common aspects of poor adherence appreciated in this 
study were inadequate daily execution of the prescribed drug regimen and early 
discontinuation of treatment.65  The patients are assumed to fully comply with esketamine 
and brexanolone treatment due to the fact that these medications must be administered by 
a medical professional.  Escitalopram is the most suitable for chronic treatment because it 
is administered orally.  Although patient compliance is not complete in oral SSRI 
treatment, it is a more convenient and a less invasive treatment.  In terms of practicality 
of long-term treatment, esketamine is favored over brexanolone due to administration 
method.  A 60 hour IV infusion is not viable for chronic treatment.  However, the 
experimental drug SAGE-217 was developed as an oral pill in order to circumvent this 




present lower abuse liability and less patient expense.59   If oral formulations were 
approved for esketamine and brexanolone, adherence to treatment may suffer.   
Escitalopram, and other serotonergic agents, have shown through extensive study 
to be effective first-line antidepressant treatments.  However, glutamatergic and GABAA 
modulating mechanisms show great promise for future antidepressant therapy.  
Esketamine and brexanolone were effective in treating depression subtypes and did not 
pose any serious health risks.  The main differentiating factor between current 
antidepressants and these drugs is the rapid antidepressant response.  This rapid response 
may be most beneficial for patients in which a fast relief of symptoms is of more 
importance.  Such patient populations include those suffering from severe MDD or 
suicidal depression.  These medications were administered at medical facilities and 
allowed for complete patient compliance and monitoring.  Research focus should be 
shifted from drugs with extensively researched mechanisms of action, like SSRIs, to 
glutamatergic and GABAergic targeting drugs.  At this point, a determination cannot be 
made as to which of these two new types of antidepressants, esketamine or brexanolone, 
shows the greater promise in future depression treatment.  Antidepressant research should 
be focused on studying the efficacy and safety of drugs with these two novel mechanisms 
of action in the broader MDD population.  If proven to be safe and effective in this 
population, implementing monotherapy and treatment augmentation, with such drugs, 
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